Welcome to our dedicated page for Madrigal Pharmaceuticals news (Ticker: MDGL), a resource for investors and traders seeking the latest updates and insights on Madrigal Pharmaceuticals stock.
Madrigal Pharmaceuticals, Inc. develops and commercializes therapies for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease that can progress to cirrhosis and liver failure. Its principal medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist approved by the FDA and European Commission for MASH with moderate to advanced fibrosis.
Company news regularly covers Rezdiffra sales and patient adoption, quarterly financial results, regulatory and clinical development updates, and pipeline expansion through licensed assets such as ARO-PNPLA3, a clinical-stage siRNA program targeting PNPLA3, and an oral GLP-1 receptor agonist program. Madrigal also issues recurring corporate-governance updates, including Nasdaq inducement awards under its employee equity plans.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) licensed ARO-PNPLA3 to Madrigal Pharmaceuticals in an exclusive global agreement announced May 5, 2026. Phase 1 data published in The New England Journal of Medicine showed up to 46% liver fat reduction in PNPLA3 I148M homozygous patients.
Financial terms: $25 million upfront, up to $975 million in milestones, and tiered royalties in the high-single digits to mid-teens.
Madrigal Pharmaceuticals (Nasdaq: MDGL) will release first-quarter 2026 financial results on Wednesday, May 6, 2026, prior to the U.S. market open. Management will host a live webcast at 8:00 a.m. Eastern Time to review financial and operating results, accessible via the company Investor Relations website.
The live webcast is recommended to be accessed by registering at least 15 minutes early and will be available on-demand about two hours after the live event.
Madrigal Pharmaceuticals (NASDAQ:MDGL) granted inducement equity awards on April 1, 2026 to 12 new non-executive employees under its 2025 Inducement Plan.
The company issued a total of 5,758 time-based restricted stock units, vesting in four equal annual installments beginning on the first anniversary, subject to continued employment and approved under Nasdaq Rule 5635(c)(4).
Madrigal Pharmaceuticals (NASDAQ:MDGL) granted inducement equity awards on April 1, 2026 to 20 new non-executive employees under its 2025 Inducement Plan.
The independent Compensation Committee approved a total of 8,079 time-based restricted stock units that vest in four equal annual installments, subject to continued employment.
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced it granted inducement equity awards on March 15, 2026 to seven new non-executive employees under its 2025 Inducement Plan.
The company granted an aggregate of 1,739 time-based restricted stock units, approved by the independent Compensation Committee under Nasdaq Listing Rule 5635(c)(4). All RSUs vest in four equal annual installments on each of the first through fourth anniversaries, subject to continued employment.
Madrigal Pharmaceuticals (NASDAQ:MDGL) granted inducement equity awards on March 1, 2026 to 20 new non-executive employees under its 2025 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards total options to purchase 789 shares and 6,882 RSUs, with options priced at $432.00 (closing price on grant date) and time‑based vesting over four years subject to continued employment.
Madrigal Pharmaceuticals (Nasdaq: MDGL) will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 2:30 P.M. ET. The presentation will be webcast live and can be accessed via the company’s Investor Relations Events page. A replay will be available after the event.
Madrigal Pharmaceuticals (NASDAQ: MDGL) reported fourth-quarter and full-year 2025 net sales of $321.1M and $958.4M, respectively, with more than 36,250 patients on Rezdiffra as of year-end 2025. Cash and marketable securities totaled $988.6M at Dec. 31, 2025.
Key 2025 developments include Orange Book patent protection into 2045, EU launch in Germany, a $350M initial term loan within a $500M credit facility, licensing deals for siRNA programs and oral GLP-1 (MGL-2086), and a Phase 2 DGAT-2 license for ervogastat.
Madrigal Pharmaceuticals (NASDAQ:MDGL) granted equity inducement awards on Feb 15, 2026 to five new non-executive employees under its 2025 Inducement Plan, approved by the independent Compensation Committee under Nasdaq Listing Rule 5635(c)(4).
The awards total 2,749 time-based restricted stock units that vest in four equal annual installments on each of the first through fourth anniversaries of the grant date, subject to continued employment on each vesting date.
Madrigal Pharmaceuticals (NASDAQ: MDGL) secured an exclusive worldwide license from Ribo and Ribocure for six pre-clinical siRNA programs targeting metabolic dysfunction-associated steatohepatitis (MASH).
Terms include a US$60M upfront, potential cumulative payments up to US$4.4B for milestones, and royalties on net sales. The deal uses Ribo's GalSTAR™ liver-targeting siRNA platform with options to expand into bi-specific siRNAs.